Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2013

View Archived Issues

Novel macrocycles for diabetes discovered at Harvard College

New anti-ICAM-1 MAbs developed in Korea

FAK inhibitors described at Merck & Co.

Roche issues overview of 2012 activities

AbbVie provides overview of 2012, looks ahead to 2013

VG Life Sciences reports results from sorafenib combination trial

Vitamin D deficiency linked to sepsis risk and outcomes

Hypertension treatment nebivolol investigated in Alzheimer's disease model

Combined viral vaccines developed at Novartis

Tricyclic pim kinase inhibitors reported by the Spanish CNIO

Relaxin fusion polypeptides developed at Bayer

MAbs to CCR6 developed at Kyowa Hakko Kirin

New genetic variants identified linked to autism spectrum disorders

AC Immune to discontinue development of ACI-91

Teva Pharmaceutical terminates agreements with CureTech

Phase II study under way for Cerulean's CRLX-101 in relapsed SCLC

Merck & Co. submits BLA for grass allergy immunotherapy tablet

Novel compounds described as potential therapies for nerve agent poisoning

BTG submits Varisolve NDA

Vernalis' drug discovery collaboration with Genentech yields milestone payment

FDA approves Ravicti for urea cycle disorders

Wellcome Trust award supports phase I/II trial of Newron's sNN-0029

Health Canada grants approval to Adcetris for two lymphoma indications

Alchemia reaches original enrollment target in phase III study of HA-irinotecan

Lyxumia approved in E.U. as first once-daily prandial GLP-1 receptor agonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...